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ABSTRACT
Introduction: In 2012, the Advisory
Committee on Immunization Practices (ACIP)
revised recommendations for adult
pneumococcal vaccination to include a
sequential regimen of 13-valent pneumococcal
conjugate vaccine (PCV13) followed by
23-valent pneumococcal polysaccharide
vaccine (PPSV23) for certain high-risk adults
with immunocompromising conditions. This
study, from a payer perspective, examined: (1)
the cost-effectiveness of the new 2012 ACIP
vaccine policy recommendation relative to the
1997 ACIP recommendation; (2) the cost-
effectiveness of potential future pneumococcal
vaccination policies; and (3) key assumptions
that influence study results.
Methods: A staticcohortmodel that incorporated
costs, health outcomes, and quality-adjusted life-
year (QALY) losses associated with invasive
pneumococcal disease and non-bacteremic
pneumococcal pneumonia (NBPP) was
developed to evaluate seven pneumococcal
vaccination strategies for a 50-year-old adult
cohort over a 50-year period using incremental
cost-effectiveness ratios (ICERs).
Results: For objective 1, the 2012 ACIP
recommendation is the more economically
efficient strategy (ICER was $25,841 per QALY
gained vs. no vaccination). For objective 2, the
most efficient vaccination policy would be to
maintain the 2012 recommendation for PPSV23
for healthy and immunocompetent adults
with comorbidities, and to modify the
recommendation for adults with
immunocompromising conditions by
replacing PPSV23 with a sequential regimen of
PCV13 and PPSV23 at age 65 (ICER was $23,416
per QALY gained vs. no vaccination). For
objective 3, cost-effectiveness ratios for
alternative pneumococcal vaccine policies
were highly influenced by assumptions used
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for vaccine effectiveness against NBPP and
accounting for the herd protection effects of
pediatric PCV13 vaccination on adult
pneumococcal disease.
Conclusion: Modifying the 2012
recommendation to include an additional dose
of PCV13 at age 65, followed by PPSV23, for
adults with immunocompromising conditions
appears to be a cost-effective vaccine policy.
Given the uncertainty in the available data and
the absence of key influential data,
comprehensive sensitivity analyses should be
conducted by policy-makers when evaluating
new adult pneumococcal vaccine strategies.
Keywords: Cost-effectiveness; Health
outcomes; Pneumococcal vaccination; Quality-
adjusted life-year; Vaccine effectiveness
INTRODUCTION
Of the two pneumococcal vaccines currently
approved for use in adults in the United States
(US), Europe, and selected other countries, the
23-valent pneumococcal polysaccharide
vaccine (PPSV23) is the only vaccine
recommended by the US Advisory Committee
on Immunization Practices (ACIP) and several
other countries for all adults 65 years of age and
older as well as younger adults with certain
chronic conditions [1]. Like PPSV23, the
13-valent pneumococcal conjugate vaccine
(PCV13) has been approved by the US Food
and Drug Administration and selected other
regulators for vaccination of adults aged
50 years and older. The basis for licensure for
the adult indication for PCV13 relies on its non-
inferior immunogenicity for matched serotypes,
when compared to adult responses to PPSV23
[2]. There is no known correlate of protection,
or antibody level at which a clinical effect
would be expected, for pneumococcal disease
in adults, hence it is not possible to translate
such immunogenicity measures into expected
efficacy or effectiveness measure [1].
In February 2012, the US ACIP chose to
continue its 1997 recommendation for routine
adult use of PPSV23 rather than recommend
routine use of PCV13, until more data become
available related to clinical effectiveness of
PCV13 and the magnitude of indirect
reduction in adult disease due to routine
vaccination of children with PCV13 [2, 3]. In
June 2012, the ACIP voted to recommend a
sequential regimen of PCV13 and PPSV23
for certain high-risk adults with
immunocompromising conditions, functional
or anatomic asplenia, cerebrospinal leaks, or
cochlear implants. These recommendations
were published in October 2012 [1].
The ACIP decision-making process included
assessments of cost-effectiveness data
comparing PCV13 and PPSV23 in adults. Such
cost-effectiveness models require explicit
assumptions of effectiveness to be specified;
however, there are neither any published
clinical-outcomes data that compare the two
vaccines in adult populations, nor are there any
published trials evaluating the efficacy or
effectiveness of PCV13 in healthy adults
against either invasive pneumococcal disease
(IPD) or non-bacteremic pneumococcal
pneumonia (NBPP). Several clinical trials and
observational studies have evaluated the
efficacy and effectiveness of PPSV23 in
preventing both invasive and non-invasive
diseases [4–6], and there are several meta-
analyses of these data [7–9]. The data are
consistent regarding PPSV23 effectiveness for
invasive disease; however, there are
inconsistent meta-analysis results and
interpretations regarding PPSV23 effectiveness
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for preventing non-invasive disease (i.e., NBPP)
[7, 8].
Recently published economic analyses
described the potential economic impact of
different adult pneumococcal vaccine
regimens. A paper by Smith et al. [9] modeled
the potential economic impact of various
vaccination strategies on pneumococcal
disease among adults 50 years of age and
older. This analysis compared PCV13 to
PPSV23, concluding that routine use of PCV13
at ages 50 and 65 would be the most
economically efficient recommendation to
prevent pneumococcal disease in adults [10]. A
separate paper by Weycker et al. [11] yielded
similar results. Results from both models were
sensitive to effectiveness assumptions for each
vaccine, and both models included the
assumption that PPSV23 was ineffective in the
prevention of NBPP [10, 11]. However, neither
of these publications explored the economic
implications of the most recent ACIP sequential
PCV13–PPSV23 regimen in selected high-risk
populations.
Hence, the main objectives of the current
analyses are to:
1. evaluate the economic implications of the
2012 ACIP recommendation compared with
the 1997 ACIP recommendation;
2. examine additional relevant vaccination
strategies that may be considered by
decision-makers in the future, and;
3. explore the implications of various
assumptions including those pertaining to
vaccine effectiveness and herd protection
on cost-effectiveness conclusions.
METHODS
All appendices mentioned below can be found
in the supplementary material published
alongside the online version of this article.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Model Structure
A static cohort model with a 1-year cycle
length was developed in Microsoft Excel
(Microsoft Corporation, Albuquerque, NM,
USA). The model projects the lifetime risk
and associated costs and quality-adjusted
life-years (QALY) associated with IPD and
NBPP in a hypothetical US 50-year-old adult
cohort for a period of 50 years or until
death. A 3% discount rate for costs and
benefits was used.
Based on risk and outcome of pneumococcal
disease, five health states are modeled (see
Appendix 1):
1. Healthy: immunocompetent adults with no
comorbid conditions;
2. Immunocompetent adults with
comorbidities [i.e., immunocompetent
adults diagnosed with certain chronic
conditions that moderately increase the
risk of pneumococcal disease (e.g.,
diabetes, heart disease, lung disease)];
3. Immunocompromised: adults at greatly
increased risk of pneumococcal disease
(immunocompromising conditions include
certain cancers, immunosuppression due to
chemotherapy, radiation therapy, or bone-
marrow transplant, asplenia, human
immunodeficiency virus infection, and
others);
4. Disabled: disability may occur after IPD or
NBPP, and;
5. Death: death may be due to pneumococcal
disease or other causes.
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Persons in the first three states may develop
pneumococcal disease. Disease outcomes
include outpatient visits for NBPP,
hospitalizations for IPD and NBPP, and death
or long-term disability associated with IPD and
NBPP. Depending on the outcomes of the
diseases, persons can remain at the same state,
or may move to other states. Background
mortality rates from other causes are
incorporated into the model, so the total
population at risk of pneumococcal disease is
reduced in each simulated year (Fig. 1). Annual
age-specific transition probabilities among risk
groups were derived from Weycker et al. [12]
(see Table S9 in Appendix 1, Distribution of Risk
Groups). Vaccination strategies were assumed to
reduce the baseline risk of pneumococcal
disease.
Vaccination Strategies
Given the need to assess two vaccines, three risk
categories, and multiple vaccination age points
in this economic analysis, many options were
considered for defining a reasonable set of
vaccination strategies that are both clinically
relevant and practically implementable. For
modeling purposes, this analysis is restricted
to vaccination strategies for adults 50 years of
age and older, for whom the 1997 ACIP
recommendation (Table 1) is applicable.
Vaccination prior to the age of 50 years is not
considered here, nor are adults who may have
been vaccinated before the age of 50.
To explore various relevant strategies that
could plausibly be implemented in the future,
we defined three broad sets of strategies,
totaling seven different vaccination strategies,
as well as the no-vaccination strategy (which
models the hypothetical disease incidence in
the absence of any adult pneumococcal
immunization; Table 2). For each set of
strategies, a logical progression of vaccine
recommendations was defined, such that
different age and health-based risk categories
were considered iteratively. The strategies
described below are not the only possible
strategies, but rather are considered plausible;
for example, a vaccination strategy where
PPSV23 is not used at all is not presented
because PPSV23 is recommended for adult use
by ACIP and multiple other national
authorities, and the strategy is weakly
dominated by other vaccination strategies
included here. These seven strategies were
developed based on current ACIP policies and
logical extensions of the policies, as well as to
include and explore vaccination strategies in
recently published adult pneumococcal
economic analyses [10, 11].
The first set of strategies describes both the
1997 ACIP recommendation (strategy 1; S1) and
the 2012 ACIP change for
immunocompromised individuals (strategy 2;
S2). The second set illustrates how a vaccination
strategy might be constructed if decision-
makers were to extend the 2012 ACIP
recommendation for a sequential PCV13–
PPSV23 regimen to include the
immunocompetent with comorbidities group
(strategy 3; S3) or both the comorbidities and
healthy groups (strategy 4; S4). The age points
for vaccination for these strategies appear in
Table 2.
The third set consists of three additional
strategies that could apply if decision-makers
preferred simple recommendations for the
majority of individuals (healthy and
immunocompetent with comorbidities) as
most practical to implement (keeping vaccine
choice more consistent and making age at
vaccination the main patient characteristic
that changes). In this set of strategies, the
recommendation for the
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Fig. 1 Health states and model structure. IPD, invasive pneumococcal disease; NBPP, non-bacteremic pneumococcal
pneumonia; w/, with
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immunocompromised group is fixed, and
different recommendations for the healthy
and immunocompetent/comorbidities groups
are explored. In strategy 5 (S5), PCV13 at age
65 is first added to the 2012 ACIP
immunocompromised recommendation, and
the healthy and immunocompetent/
comorbidities recommendations remain
unchanged. Proceeding to strategy 6 (S6), the
current PPSV23 recommendations for the
healthy group at 65 and the comorbidities
group at 50 and 65 are replaced with PCV13.
In strategy 7 (S7), the current healthy and
immunocompetent with comorbidities




Estimates of annual rates of each disease
outcome were based on data presented by
Weycker et al. [12] (see Table S2 in Appendix
1). The rates of IPD, death and disability from
IPD, hospitalized NBPP, death and disability
from NBPP, and outpatient visits associated
with NBPP were calculated, varying by age and
risk of pneumococcal status (see Appendix 1 for
description). Baseline rates of disease for the no-
vaccination strategy were estimated using
methods described previously [13].
Proportions of the population that fall into
each risk category were based on published
literature (see Table S9 in Appendix 1,
Distribution of Risk Groups) [12] and
individuals were assumed to move from lower
risk categories to higher risk categories
probabilistically as they aged in the model.
The 50-year-old cohort initially included a
population that was 52.3% healthy; 36.5%
immunocompetent with comorbidities and
11.2% immunocompromised [12].
Cost Estimates
Medical-care costs related to hospitalizations,
outpatient visits, and deaths were included in
Table 1 ACIP recommendations for the use of pneumococcal vaccines as applied to a cohort of adults 50 years and older
Time period ACIP recommendation
1997 ACIP recommendations
April 4, 1997–October 11,
2012 [2, 3]
• PPSV23 recommended for healthy adults 65 years or older, regardless of health history
• PPSV23 recommended for individuals aged 50–64 years who are immunocompetent and
have certain underlying medical conditions, as well as adults with immunocompromising




• PPSV23 recommended for healthy adults 65 years or older, regardless of health history
• PPSV23 recommended for individuals aged 50–64 years who are immunocompetent and
have certain underlying medical conditions. Re-vaccination at age 65 is also
recommended for this group
• PCV13 followed by PPSV23 are both recommended for adults with
immunocompromising conditions, as well as functional and anatomic asplenia,
cerebrospinal leaks and cochlear implants
ACIP, Advisory Committee on Immunization Practices; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23,
23-valent pneumococcal polysaccharide vaccine
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the model and varied by risk status (see Table S2
in Appendix 1) [12]. Vaccine costs were based
on Centers for Disease Control and Prevention
reports of private-sector prices as of September
10, 2012 [14]. PPSV23 was assumed to be $57.70
per dose and PCV13 to be $120.95 per dose.
Administration cost was assumed to be $15.00
per dose for each product. Indirect costs were
not included in this analysis. Costs are
expressed in 2012 US dollars using medical
Consumer Price Index adjustor [15].
Utility Weights
Utility weights associated with IPD and NBPP
inpatient cases, as well as baseline utilities for
average- and high-risk populations were based
on values described by Smith et al. [9] (see Table
S9 in Appendix 1). Utility weights associated
with outpatient visits for NBPP were based on
estimates related to influenza outpatient visits
[10]. Duration of an event is incorporated in
QALY calculation.
Vaccine Uptake
Vaccine uptake was assumed to vary depending
on age and risk category and was based on
contemporary US data regarding PPSV23 (see
Table S9 in Appendix 1). Vaccine uptake for
both PCV13 and PPSV23 was assumed to be the
same for each age/risk category described. For
routine age-based recommendations (at age
50 years or age 65 years), vaccine uptake was
assumed to be 12.0% for healthy, 33.9% for
immunocompetent with comorbidities and
immunocompromised populations at age
50 years, and 60.1% for all risk categories at
age 65 years.
Vaccine Effectiveness
Due to the absence of data comparing PCV13 to
PPSV23 efficacy in adults, assumptions around
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well as PPSV23 effectiveness against NBPP were
based on expert opinion using estimates
generated from a Delphi panel engaged in
2011 for healthy and immunocompetent with
comorbidities groups (Table 3; see Appendix 2
for description of Delphi methods). PPSV23
effectiveness against IPD for the healthy and
immunocompetent with comorbidities groups
was based on Moberley et al. [7] and Smith et al.
[9]. Effectiveness estimates described at the June
2012 ACIP meeting were used for the
immunocompromised risk group [16] (Table 3;
see Appendix 1 for description of the estimation
of vaccine effectiveness). In the base-case
analysis, PPSV23 was assumed to wane over a
period of 10 years. PCV13 was assumed to be
effective in healthy adults, as well as
immunocompetent adults with chronic
conditions and immunocompromised
populations. There are no long-term efficacy
data available for PCV13 in adults, so it was
assumed to wane over a period of 15 years in
Table 3 Pneumococcal vaccine serotype-speciﬁc effectiveness estimates in the ﬁrst year after vaccination for healthy and,
immunocompetent with comorbidities, and immunocompromised adult populations
Manifestation,








Invasive pneumococcal disease (IPD)
PPSV23
50 82.7 70.3 18.0
65 73.8 62.7 16.1
PCV13
50 80.0 67.5 53.0
65 72.5 61.2 48.0
Non-bacteremic pneumococcal pneumonia (NBPP)
PPSV23
50 49.5 36.5 0
65 36.5c 26.9 0
PCV13
50 68.0 56.0 7.0
65 60.5 49.8 6.2
ACIP, Advisory Committee on Immunization Practices; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23,
23-valent pneumococcal polysaccharide vaccine; UBC, United BioSource Corporation
a Source for effectiveness assumptions for healthy and immunocompetent with comorbidities based on internal report from
UBC Delphi panel report (October 29, 2011)
b Source for immunocompromised effectiveness assumptions: June 2012 ACIP presentation [14]. UBC Delphi panel did
not collect estimates for immunocompromised population, so data from 2012 ACIP analysis was used
c Consensus of the Delphi panel was not reached for this estimate. The a priori protocol deﬁned consensus as 70% of
panelist estimates falling within one standard deviation of the mean. For this estimate 60% of estimates were within one
standard deviation of the mean
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this model. All vaccine-waning patterns were
assumed to be linear.
Projected vaccine impact on disease was
based on the effectiveness estimates described
in Table 3, along with vaccine uptake and
vaccine serotype coverage. Based on
surveillance data from 2008, PPSV23 was
assumed for the base-case to cover 75.7% of all
IPD and NBPP in adults 50–64 years of age, and
64.7% of disease in adults 65 and older. PCV13
was assumed to cover 52.6% of IPD and NBPP in
adults 50–64 years of age and 49.9% of disease
in those 65 years of age and older [17].
Sensitivity Analyses
Given the uncertainty around several key model
parameters, sensitivity analyses are critical to
understanding the potential economic
implications of the various vaccination
strategies explored. Sensitivity analyses were
conducted to examine the impact of varying
assumptions related to vaccine effectiveness,
impact of herd protection on disease incidence
and vaccine serotype coverage. In addition, a set
of scenario analyses was conducted to examine
the potential cost-effectiveness of broad age-
based vaccine recommendations starting at age
50.
Projected Impact of Herd Protection
To be conservative, the impact of herd
protection was excluded in the base case. To
assess model sensitivity to the impact of herd
protection on disease incidence and serotype
coverage, additional scenarios were evaluated,
anticipating some future point when full
reduction in adult disease due indirectly to
pediatric PCV13 has been realized. Data related
to reductions in IPD observed after routine
pediatric use of 7-valent pneumococcal
conjugate vaccine (PCV7) were applied to the
modeled base-case rates of disease to generate
projected disease-incidence rates after routine
pediatric use of PCV13 [17]. In that future
scenario, IPD and NBPP disease reductions
post-PCV13 were assumed to be comparable to
those seen for IPD reductions post-PCV7.
There are sufficient surveillance data to
indicate that a significant herd impact post-
PCV7 introduction has already occurred in the
US, however, there is no consensus in the
published literature regarding the potential
herd impact of use of PCV7 on NBPP in adults
[18, 19].
The projected herd-impact parameters varied
based on certain serotype characteristics.
Disease incidence associated with serotypes
contained in PCV7 as well as serotypes 1 and 5
were assumed to remain at current low levels.
Serotypes 1 and 5 are believed to behave
differently than other serotypes in terms of
carriage and transmission, so it is not clear how
adult disease related to these two serotypes
would be affected by pediatric use of PCV13.
The incidence of disease associated with the
four other new serotypes in PCV13 was assumed
to decrease in a pattern similar to the observed
reductions in PCV7 types after routine pediatric
vaccination began. All other serotypes (PPSV23
unique types and non-vaccine types) were
assumed to increase slightly, similar to
increases observed post-PCV7 implementation.
Serotype coverage for each vaccine was
assumed to vary and three sets of assumptions
were applied to three separate sensitivity
analyses:
1. Full herd impact: PPSV23 was assumed to
cover 68% of disease in adults aged
50–64 years and PCV13 20%; PPSV23 was
assumed to cover 56% of disease in adults
older than 65 years, and PCV13 18%;
2. Herd impact was assumed to be 50% of that
projected for scenario 1;
Adv Ther (2014) 31:392–409 401
3. Herd impact for IPD described as in scenario
1, but no herd impact assumed for NBPP. In
this scenario NBPP rates of disease and
serotype distributions were equivalent to
base-case assumptions.
Waning of Effectiveness
Recent studies demonstrate that PPSV23
induces antibody responses that remain above
the levels of unvaccinated adults for 5–10 years
or more [20]. Little long-term effectiveness data
are available for PCV13 in adults. To understand
the impact of waning assumptions of cost-
effectiveness results, three sensitivity analyses
were generated:
1. PCV13 and PPSV23 were assumed to have
equivalent waning rates of 10 or 15 years;
2. PCV13 was assumed to wane over a period
of 20 years, rather than 15 years as in the
base case.
RESULTS
Projected Pneumococcal Disease Events
Total projected IPD cases (survived), NBPP
hospitalizations (survived), disabled cases
(survived), outpatient visits, and deaths for the
no-vaccination strategy, along with the
projected events averted for the seven
vaccination strategies were generated (Table 4).
The model projects that for a single cohort of
100,000 adults starting at age 50 years, in the
absence of pneumococcal vaccination, there
Table 4 Clinical events and deaths expected (for no-vaccination strategy) and averted (for all other strategies), for a single

















No vaccination 870 12,445 7,689 340 1,571
Events averted vs. S0
(S1): 1997 ACIP recommendations 30 99 40 4 13
(S2): 2012 ACIP recommendations 38 110 43 4 16
(S3): (same as S2, but [C]: PCV13–PPSV23) 46 172 60 6 19
(S4): (same as S3, but [H]: PCV13–PPSV23) 47 195 74 6 21
(S5): (same as S2, but [I]: PCV13–PPSV23 at
65 years)
50 140 58 6 23
(S6): (same as S5, but [H] and [C] all start with
PCV13)
51 235 105 8 28
(S7): (same as S5, but [H], [C], [I] all start with
PCV13–PPSV23)
57 260 115 8 31
ACIP, Advisory Committee on Immunization Practices; [C], Immunocompetent with comorbidities; [H], Healthy adults;
[I], Immunocompromised adults; IDP, invasive pneumococcal disease; NBPP, non-bacteremic pneumococcal pneumonia;
PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine
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would be 870 IPD cases, 12,445 NBPP outpatient
visits, 7,689 NBPP hospitalizations, and 340
disabled cases due to IPD/NBPP. Total projected
events averted for each of the vaccination
strategies indicate that strategy 7 would
prevent the most events compared to all other
strategies (Table 4).
Economic Evaluation
For objective 1, three strategies were compared:
no vaccination, as well as S1 (1997 ACIP
recommendations) and S2 (2012 ACIP
recommendations). In this first comparison, S2
is the most economically efficient strategy with
an incremental cost-effectiveness ratio (ICER) of
$25,841 per QALY gained, compared with no
vaccination, and S1 is dominated.
For objective 2, four possible future
vaccination strategies were added to the
comparison (Table 5). The most economically
efficient strategy is S5, with an ICER of
$23,416 per QALY gained compared to no
vaccination. S6 had an ICER of $124,665 per
QALY gained compared with S5. S7 had an
ICER of $182,067 per QALY gained compared
to S6. Other strategies are either dominated or
less efficient.
Sensitivity Analysis Results
Sensitivity analyses related to impact of disease
incidence and serotype changes and due to herd
protection along with changes to vaccine
effectiveness assumptions are reported in
Table 6.
Table 5 Model results for the base case ordered by increasing cost per person










No vaccination $932.88 13.7825 – – –
(S1): 1997 ACIP recommendations $954.92 13.7833 Less efﬁcient than S2
(S2): 2012 ACIP recommendations $959.58 13.7835 Less efﬁcient than S5
(S5): (same as S2, but [I]: PCV13–PPSV23
at 65 years)
$962.71 13.7838 $29.83a 0.00127a $23,416a
(S3): (same as S2, but [C]: PCV13–PPSV23) $978.50 13.7838 Less efﬁcient than S6
(S4): (same as S3, but [H]: PCV13–PPSV23) $997.34 13.7839 More costly, lower beneﬁt than S6
(S6): (same as S5, but [H] and [C] all start with
PCV13)
$983.55 13.7840 $20.84b 0.00017b $124,665b
(S7): (same as S5, but [H], [C], [I] all start with
PCV13–PPSV23)
$1,010.28 13.7841 $26.72c 0.00015c $182,067c
Incremental costs and QALY and ICER calculations are shown for non-dominated strategies based on pairwise comparisons
ACIP, Advisory Committee on Immunization Practices; [C], Immunocompetent with comorbidities; [H], Healthy adults;
[I], Immunocompromised adults; ICER, incremental cost-effectiveness ratio; PCV13, 13-valent pneumococcal conjugate
vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; QALY, quality-adjusted life-year
a S5 vs. no vaccination
b S6 vs. S5
c S7 vs. S6
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Table 6 Sensitivity analysis results: rank order of three most economically efﬁcient vaccination strategies and associated
ICERs
Parameters varied Assumption Rank order of most (1) to least (3)
economically efﬁcient vaccination
strategies [strategy (S) and ICER in US$]
1 2 3
None Base case S5 S6 S7
23,000 125,000 182,000
Changes in incidence of disease
and serotype distribution due to
herd protection
Full herd impact S1 S2 S5
51,000 77,000 103,000
50% herd impact S5 S7
36,000 266,000
No herd impact on NBPP S1 S5 S3
41,000 50,000 151,000
PPSV23 effectiveness against NBPP Increase by 10% S5 S6 S7
22,000 150,000 173,000
Decrease base case by 10% S5 S6 S7
24,000 106,000 192,000
Decrease base case by 80% S5 S6 S7
32,000 46,000 291,000
Decrease base case by 100% S5 S6 S7
35,000 39,000 337,000
PPSV23 and PCV13 effectiveness
waning rates




PPSV23 wanes over 10 years, PCV13
wanes over 20 years
S5 S6 S7
20,000 49,000 182,000




Only non-dominated strategies are shown. Dominated strategies could have been eliminated from consideration due to
strong dominance (i.e., a less expensive and more beneﬁcial strategy available), or weak dominance (i.e., a more economically
efﬁcient strategy available). Incremental cost-effectiveness ratios are compared as follows: rank 1 vs. no vaccination, rank 2
vs. rank 1, and rank 3 vs. rank 2. Several sensitivity analyses had more than three non-dominated strategies, but only the top
three strategies are shown. Full herd impact projections based on changes in adult IPD observed post-introduction of
7-valent pneumococcal conjugate vaccine [17]
ICER, incremental cost-effectiveness ratio; IPD, invasive pneumococcal disease; NBPP, non-bacteremic pneumococcal
pneumonia; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine;
US$, United States dollars
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Herd Protection
The potential impact on cost-effectiveness
results due to projected changes in disease
incidence for both IPD and NBPP along with
serotype coverage for each vaccine was
examined using three sensitivity analysis
scenarios. For the first scenario, simulating the
impact of full herd protection, the three most
economically efficient strategies were S1
($51,000 vs. no vaccination), followed by S2
($77,000 vs. S1) and S5 ($103,000 vs. S2). If 50%
less herd impact were to occur, S5 would be the
most economically efficient ($36,000 vs. no
vaccination), followed by S7. When it was
assumed that herd protection did not impact
incidence of NBPP, S1 was found to be the most
economically efficient strategy followed by S5
and S3 (Table 6).
PPSV23 Effectiveness Against NBPP
When PPSV23 vaccine effectiveness for
preventing NBPP was assumed to be 10%
greater than base case in the first year post-
vaccination, the order of preferred vaccination
strategies in the economic analysis were
maintained but with ICERs reduced.
Reductions in PPSV23 effectiveness (from
10% to 100% less relative to first year post-
vaccination in the base case) did not affect S5 to
be the most economically efficient strategy. But
the economic efficiency for S6 improved
substantially, with ICER reducing from
$150,000 to $39,000 against S5. When PPSV23
effectiveness against NBPP was decreased by
100% (i.e., assumed to be 0) versus base case, S5
and S6 became similarly efficient (ICER $35,000
and $36,000, respectively, per QALY gained vs.
no vaccination).
Waning of Effectiveness
Vaccine-waning patterns were found to impact
cost-effectiveness results in the sensitivity
analyses. When the two vaccines were
assumed to have equivalent waning periods of
10 years, the most economically efficient
strategies were S1 followed by S2 and S5, and
all had ICERs below $50,000 per QALY.
DISCUSSION
The results of this analysis are intended to
provide insight into the cost-effectiveness of
alternative pneumococcal vaccination policies
for adults in the United States. Although there is
no consensus on a threshold for good value for
resources expended, we present our results in
the context of commonly cited thresholds of
incremental cost per QALY of $ 50,000 or
$100,000 [21]. The base-case results indicate
that the 2012 ACIP recommendations for adults
with certain immunocompromising and other
conditions that place them at highest risk for
pneumococcal disease would be considered
cost-effective when compared to the 1997
ACIP recommendations. When exploring
future potential vaccination strategies, we
found the most efficient strategy to be similar
to the 2012 ACIP recommendations, with the
addition of another dose of PCV13 for the
immunocompromised population at age 65,
followed by the usual dose of PPSV23.
Several limitations related to availability of
data apply to this analysis. No trials with
clinical disease endpoints comparing these two
vaccines are available. There are no clinical
efficacy data available for PCV13 in healthy
adults, nor are there data available related to the
duration of PCV13 effectiveness in adults.
Diagnosis of NBPP is challenging, as most
pneumonia episodes are evaluated and treated
empirically, without determination of etiology.
Disease-incidence estimates were generated
based on a published analysis of
hospitalization databases [12]. There were no
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data available related to serotype distribution
for NBPP, so serotype distributions for NBPP
were assumed to be the same as for IPD. Several
limitations relate to assumptions used in
sensitivity analysis around impact of herd
protection. Two older publications reported
conflicting findings: an analysis of claims-
based data suggests that there has been no
significant impact of PCV7 on adult NBPP [18];
however, another study, utilizing different
methods and incorporating techniques to
adjust for seasonality and to address
limitations in data sources, reported significant
declines in NBPP in adults post-PCV7
introduction [19]. A more recent study
estimated that there has been a substantial
reduction in adult pneumonia hospitalizations
during the post-PCV7 vaccine introduction
years (2007–2009) compared with the pre-
PCV7 years (1997–1999) [22]. Additionally, our
model is based on a US 50-year-old cohort and
does not consider cohorts of differing ages..
When our sensitivity analyses accounted for
the herd effects of pediatric use of PCV13 on
adult disease, we found that vaccination
strategies including PCV13 may not be
efficient if adult disease due to the 13
serotypes is reduced more than 50% from pre-
PCV13 levels. In that scenario, we found the
most efficient pneumococcal vaccination policy
to be the 1997 ACIP recommendation. Our
accounting for the herd effects of PCV13 may
differ from previous cost-effectiveness analyses,
insofar as neither Smith et al. [9] nor Weycker
et al. [11] assumed that routine pediatric use of
PCV13 would have a substantial impact on
NBPP in adults. Consistent evidence to support
this assumption is lacking. However, the recent
study by Griffin et al. [22] lends support for our
sensitivity analysis assumptions related to the
herd impact on NBPP in adults. Future studies
of pneumococcal pneumonia incidence data
should attempt to determine the impact of the
pediatric use of PCV13 on non-IPD in adults.
These results differ significantly from
previous analyses, due, in part, to our PPSV23
NBPP effectiveness assumptions, which were
obtained through a Delphi panel process. For
example, Smith et al. [9] also used a Delphi
panel to estimate PCV13 effectiveness against
NBPP; however, they did not report Delphi
estimates for PPSV23 effectiveness against
NBPP. Instead, the authors assumed the
effectiveness of PPSV23 was zero in the base-
case analysis [10]. Sensitivity analyses
conducted as part of the Smith et al. [9] study
indicated that if PPSV23 was assumed to be
effective in the prevention of NBPP, then a
broad recommendation for the use of PPSV23
would be the most efficient vaccination strategy
in their analyses. Their sensitivity analysis result
is consistent with our base-case findings. Even
when PPSV23 is assumed to be ineffective
against NBPP, our sensitivity analysis showed
that S5 (adding PCV13 to
immunocompromised group only) is still the
most efficient although the efficiency of S6
(substituting PCV13 for PPSV13 for healthy and
immunocompetent in addition to adding
PCV13 to immunocompromised group)
approached S5. However, it is expected that S6
will have a significantly larger budget impact
given the cost of PCV13. Another economic
analysis recently published by Weycker et al.
[11] also reported results that favored broad
PCV13 immunization. The Weycker et al. [11]
analysis examined the impact of pneumococcal
vaccines on all-cause pneumonia, rather than
restricting the analysis to NBPP as we have
done. Weycker et al. [11] used effectiveness
assumptions similar to those used in Smith et al.
[9] for PPSV23, and they used pediatric data for
pneumonia effectiveness assumptions for adult
use of PCV13. Weycker et al. [11] did not
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explore whether their conclusions were
influenced by their assumptions regarding the
effectiveness of PPSV23 in preventing NBPP.
Furthermore, most strategies considered by
Weycker et al. [11] assumed use of PCV13 in
all adults age C50 years at model entry, which
were inconsistent with ACIP recommendations.
We evaluated strategies with vaccination at age
50 for the lower risk population (details not
reported) and found that these strategies were
less economically efficient than the seven
strategies explored in the analysis. As a result,
we cannot compare our findings with their
results.
CONCLUSION
The 2012 ACIP recommendation is the more
economically efficient strategy comparing to
the 1997 ACIP recommendation. However,
modifying the 2012 recommendation to
include an additional dose of PCV13 at age 65,
followed by PPSV23, for adults with
immunocompromising conditions appears to
be a more cost-effective vaccine policy than the
2012 ACIP recommendation.
The results of our analyses demonstrate the
influence of parameters such as vaccine
effectiveness and herd protection effects on
economic evaluations of adult pneumococcal
vaccine policies. PPSV23 protects against
infection with 23 serotypes and prevents IPD,
the most serious manifestation of this infection.
Given that the herd protection effects of routine
pediatric PCV13 use are likely to reduce the
utility of PCV13 in adults, the additional
protection conferred by PPSV23 will be
important for preventing IPD due to the
serotypes not covered in PCV13. Due to the
uncertainty in available data, as well as the
absence of key influential data, comprehensive
sensitivity analyses should be conducted by
policy-makers when evaluating new
pneumococcal vaccine strategies in adults.
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